Inositol Encyclopedia — Scientific Background

What Is Inositol?

Inositol (CAS 87-89-8), also known as myo-inositol, is a naturally occurring sugar alcohol and a carbocyclic polyol with the molecular formula C₆H₁₂O₆ and a molecular weight of 180.16 g/mol. It is chemically characterized as cis-1,2,3,5-trans-4,6-cyclohexanehexol and exists as fine, white crystals or a white, crystalline powder. Inositol is optically inactive, stable in air, and freely soluble in water (1 g in 6 mL). It was formerly classified as a member of the vitamin B complex but is more accurately described as a vitamin-like substance.

Myo-Inositol vs. D-Chiro-Inositol

Of the different inositols that exist, only myo-inositol (MYO) and D-chiro-inositol (DCI) have been extensively studied in the treatment of PCOS. Myo-inositol is the most abundant form of inositol in both nature and mammalian cells, with up to 99% of the overall inositol amount. D-chiro-inositol is present in lower concentrations and is produced from myo-inositol by an NAD/NADH-dependent epimerase enzyme that is insulin-dependent and tissue-specific.

Despite their structural similarities, MYO and DCI play different roles in PCOS etiology and therapy. In reproductive tissues such as the ovary, MYO regulates glucose uptake and follicle-stimulating hormone (FSH) signaling, whereas DCI is devoted to insulin-mediated androgen production. Research shows that there is insufficient or controversial evidence to recommend the use of DCI alone, while MYO alone shows positive results, and the MYO/DCI combination is effective when used at a ratio of at least 40:1.

Mechanisms of Action

Phosphatidylinositol Signaling Pathway

Inositol is a critical precursor for phosphatidylinositol (PI), a membrane phospholipid that, upon cellular stimulation by hormones or neurotransmitters, is cleaved into second messengers including inositol triphosphate (IP₃) and diacylglycerol (DAG). These second messengers regulate intracellular calcium levels and activate protein kinase cascades, influencing cell growth, secretion, and metabolic activity. This pathway is particularly critical in insulin signal transduction and ovarian function regulation.

Insulin Sensitivity Enhancement

Myo-inositol serves as a precursor for inositol phosphoglycans (IPGs), which act as second messengers in insulin signaling. Research demonstrates that inositol improves insulin sensitivity at the cellular level, helping cells utilize glucose more efficiently and maintaining blood glucose stability. Clinical observations suggest that PCOS patients using inositol under medical guidance show improvements in insulin levels and ovarian function. In a 12-week randomized controlled trial, combination therapy with inositol produced the greatest reduction in HOMA-IR (−2.64, 95% CI −2.82 to −2.46, p < 0.001).

Ovarian Function and Ovulation Restoration

Clinical trials demonstrate that inositol supplementation can improve insulin sensitivity, reduce androgen levels, and restore ovulation in women with PCOS. Administration of myo-inositol to PCOS patients resulted in several beneficial effects, including decreased circulating insulin and serum total testosterone levels, as well as restored ovulation. Myo-inositol at 4 g/day for 3–6 months restored ovulation in 70% of PCOS patients versus 33% on placebo.

Neurotransmitter and Mood Regulation

Inositol is involved in the synthesis and signaling of serotonin, a key neurotransmitter that regulates mood, sleep, and appetite. Research suggests that inositol may help balance serotonin levels, supporting mood regulation and reducing symptoms of anxiety and depression. High doses of myo-inositol (up to 18 g per day) have been studied for their potential to support neurotransmitters like serotonin, which regulates mood and anxiety.

The Bioavailability Challenge

Despite its essential physiological functions, native inositol presents significant formulation challenges. The compound has a large effective dose requirement (typically 4 g/day for PCOS management), is rapidly cleared by the kidneys, and exhibits limited passive diffusion across intestinal membranes. These factors limit its practical utility and clinical efficacy, particularly for chronic conditions requiring sustained supplementation.

liposomal encapsulation addresses these limitations through a phospholipid bilayer that protects inositol during digestive transit, enhances intestinal absorption through lipid-mediated pathways, and provides sustained release for prolonged cellular signaling support.

Liposomal Inositol

Liposomal encapsulation of inositol provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the inositol molecule, forming a protective shell that enhances absorption and facilitates sustained release. This delivery system:

• Protects inositol from rapid renal clearance and excretion

• Enhances intestinal absorption through lipid-mediated pathways

• Provides sustained release for prolonged cellular signaling support

• Enables more efficient utilization of lower doses

Clinical Evidence

PCOS Management

A 12-week randomized controlled trial in 192 women aged 18–35 years with PCOS evaluated inositol (myo-inositol 2 g plus D-chiro-inositol 50 mg twice daily) compared with metformin, dietary restriction, and combination therapy. All interventions improved metabolic and endocrine parameters. Inositol supplementation achieved menstrual cyclicity improvement in 64.6% of participants, compared with 39.6% for metformin, 72.9% for dietary restriction, and 85.4% for combination therapy (p < 0.001).

Insulin Sensitivity

Myo-inositol at 4 g/day for 3–6 months restored ovulation in 70% of PCOS patients versus 33% on placebo, reduced LH and testosterone levels, and improved insulin sensitivity. Combination therapy with metformin, inositol, and dietary restriction resulted in the greatest reduction in HOMA-IR (−2.64, 95% CI −2.82 to −2.46, p < 0.001) and BMI (−2.8 kg/m², 95% CI −3.05 to −2.55, p < 0.001).

Mood and Anxiety Support

Inositol is believed to have a positive effect on mental health, including reducing symptoms of anxiety and depression. It has been found to help balance levels of neurotransmitters in the brain, such as serotonin, which can help improve mood and reduce symptoms of anxiety and depression. Research suggests that high doses of myo-inositol (up to 18 g per day) may support neurotransmitters like serotonin.

Safety and Regulatory

Myo-inositol is generally well tolerated at commonly used doses. Doses of 2–4 g/day are considered safe in standard randomized controlled trials. For mood and anxiety support, higher doses up to 18 g/day have been used in clinical studies. Common side effects may include gastrointestinal discomfort, nausea, and diarrhea at high doses. Myo-inositol is widely commercialized as a dietary supplement ingredient and is used in pharmaceutical and food applications. In the United States, myo-inositol is generally recognized as safe (GRAS) for use in food and dietary supplements. USP has established a reference standard for Inositol (Catalog No. 1340960). Testing protocols must adhere to international standards including USP, European Pharmacopoeia, FAO/WHO Codex Alimentarius, and ISO 20637:2015 for myo-inositol determination. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

69$/KG